Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 Jun 1;160(11):1557–1563.

End-stage renal disease in Canada: prevalence projections to 2005

D E Schaubel 1, H I Morrison 1, M Desmeules 1, D A Parsons 1, S S Fenton 1
PMCID: PMC1230359  PMID: 10373996

Abstract

BACKGROUND: The incidence and prevalence of end-stage renal disease (ESRD) have increased greatly in Canada over the last 2 decades. Because of the high cost of therapy, predicting numbers of patients who will require dialysis and transplantation is necessary for nephrologists and health care planners. METHODS: The authors projected ESRD incidence rates and therapy-specific prevalence by province to the year 2005 using 1981-1996 data obtained from the Canadian Organ Replacement Register. The model incorporated Poisson regression to project incidence rates, and a Markov model for patient follow-up. RESULTS: Continued large increases in ESRD incidence and prevalence were projected, particularly among people with diabetes mellitus. As of Dec. 31, 1996, there were 17,807 patients receiving renal replacement therapy in Canada. This number was projected to climb to 32,952 by the end of 2005, for a relative increase of 85% and a mean annual increase of 5.8%. The increased prevalence was projected to be greatest for peritoneal dialysis (6.0% annually), followed by hemodialysis (5.9%) and functioning kidney transplant (5.7%). The projected annual increases in prevalence by province ranged from 4.4%, in Saskatchewan, to 7.5%, in Alberta. INTERPRETATION: The projected increases are plausible when one considers that the incidence of ESRD per million population in the United States and other countries far exceeds that in Canada. The authors predict a continued and increasing short-fall in resources to accommodate the expected increased in ESRD prevalence.

Full Text

The Full Text of this article is available as a PDF (140.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Desmeules M., Schaubel D., Fenton S. S., Mao Y. New and prevalent patients with end-stage renal disease in Canada. A portrait of the year 2000. ASAIO J. 1995 Apr-Jun;41(2):230–233. [PubMed] [Google Scholar]
  2. Farrow S. C., Fisher D. J., Johnson D. B. Dialysis and transplantation: the national picutre over the next five years. Br Med J. 1972 Sep 16;3(5828):686–690. doi: 10.1136/bmj.3.5828.686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Farrow S. C., Fisher D. J., Johnson D. B. Statistical approach to planning an integrated haemodialysis-transplantation programme. Br Med J. 1971 Jun 19;2(5763):671–676. doi: 10.1136/bmj.2.5763.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Frome E. L. The analysis of rates using Poisson regression models. Biometrics. 1983 Sep;39(3):665–674. [PubMed] [Google Scholar]
  5. Goeree R., Manalich J., Grootendorst P., Beecroft M. L., Churchill D. N. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med. 1995 Dec;18(6):455–464. [PubMed] [Google Scholar]
  6. Hakulinen T., Teppo L., Saxén E. Do the predictions for cancer incidence come true? Experience from Finland. Cancer. 1986 Jun 15;57(12):2454–2458. doi: 10.1002/1097-0142(19860615)57:12<2454::aid-cncr2820571235>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  7. Harris M. I. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993 Apr;16(4):642–652. doi: 10.2337/diacare.16.4.642. [DOI] [PubMed] [Google Scholar]
  8. Kjellstrand C. M., Moody H. Hemodialysis in Canada: a first-class medical crisis. CMAJ. 1994 Apr 1;150(7):1067–1071. [PMC free article] [PubMed] [Google Scholar]
  9. Martin M. As number of patients grows, so do critical problems facing MDs who provide dialysis. CMAJ. 1996 Mar 15;154(6):931–933. [PMC free article] [PubMed] [Google Scholar]
  10. Mendelssohn D. C., Chery A. Dialysis utilization in the Toronto region from 1981 to 1992. Toronto Region Dialysis Committee. CMAJ. 1994 Apr 1;150(7):1099–1105. [PMC free article] [PubMed] [Google Scholar]
  11. Port F. K. End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions. Kidney Int Suppl. 1995 Aug;50:S3–S6. [PubMed] [Google Scholar]
  12. Port F. K. Worldwide demographics and future trends in end-stage renal disease. Kidney Int Suppl. 1993 Jun;41:S4–S7. [PubMed] [Google Scholar]
  13. Raine A. E., Margreiter R., Brunner F. P., Ehrich J. H., Geerlings W., Landais P., Loirat C., Mallick N. P., Selwood N. H., Tufveson G. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant. 1992;7 (Suppl 2):7–35. [PubMed] [Google Scholar]
  14. Schaubel D. E., Morrison H. I., Desmeules M., Parsons D., Fenton S. S. End-stage renal disease projections for Canada to 2005 using Poisson and Markov models. Int J Epidemiol. 1998 Apr;27(2):274–281. doi: 10.1093/ije/27.2.274. [DOI] [PubMed] [Google Scholar]
  15. States B., Segal S. Levels of gamma-glutamyltranspeptidase in cultured skin fibroblasts from cystinotics and normals. Life Sci. 1980 Nov 24;27(21):1985–1990. doi: 10.1016/0024-3205(80)90419-1. [DOI] [PubMed] [Google Scholar]
  16. Young E. W., Mauger E. A., Jiang K. H., Port F. K., Wolfe R. A. Socioeconomic status and end-stage renal disease in the United States. Kidney Int. 1994 Mar;45(3):907–911. doi: 10.1038/ki.1994.120. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES